Show simple item record

First-line treatment of metastatic melanoma: role of nivolumab.

dc.contributor.author Force, Jeremy M
dc.contributor.author Salama, April KS
dc.coverage.spatial New Zealand
dc.date.accessioned 2017-10-12T15:09:50Z
dc.date.available 2017-10-12T15:09:50Z
dc.date.issued 2017
dc.identifier https://www.ncbi.nlm.nih.gov/pubmed/28243579
dc.identifier itt-6-001
dc.identifier.issn 2253-1556
dc.identifier.uri http://hdl.handle.net/10161/15631
dc.description.abstract Historically, the median overall survival of metastatic melanoma patients was less than 1 year and long-term survivors were rare. Recent advances in therapies have dramatically shifted this landscape with increased survival rates and the real possibility that long-term disease control is achievable. Advances in immune modulators, including cytotoxic T-lymphocyte antigen-4 and programmed death-1 based treatments, have been an integral part of this success. In this article, we review previous and recent therapeutic developments for metastatic melanoma patients. We discuss advances in immunotherapy while focusing on the use of nivolumab alone and in combination with other agents, including ipilimumab in advanced melanoma. One major goal in melanoma research is to optimize combination strategies allowing for more patients to experience benefit while minimizing toxicity. A better understanding of the optimal sequencing, combinations, and mechanisms underlying the development of resistance may provide evidence for rational clinical trial designs of novel immunotherapy strategies in melanoma and other cancer subtypes.
dc.language eng
dc.relation.ispartof Immunotargets Ther
dc.relation.isversionof 10.2147/ITT.S110479
dc.subject BRAF
dc.subject PD-1
dc.subject PD-L1
dc.subject checkpoint
dc.subject immunotherapy
dc.subject pembrolizumab
dc.subject resistance
dc.title First-line treatment of metastatic melanoma: role of nivolumab.
dc.type Journal article
pubs.author-url https://www.ncbi.nlm.nih.gov/pubmed/28243579
pubs.begin-page 1
pubs.end-page 10
pubs.organisational-group Clinical Science Departments
pubs.organisational-group Duke
pubs.organisational-group Duke Cancer Institute
pubs.organisational-group Institutes and Centers
pubs.organisational-group Medicine
pubs.organisational-group Medicine, Medical Oncology
pubs.organisational-group School of Medicine
pubs.publication-status Published online
pubs.volume 6


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record